Capstone Healthcare
What Makes us Different?
The government’s ever-increasing role as both regulator and payer is increasingly opaque, with massive implications for companies and investors alike. Legislators and regulators make critical decisions every day on healthcare issues that affect communities, and Capstone’s access to the policy world allows us to provide an array of insights. From micro studies of medical facilities to macro views of healthcare technology policy trends on the horizon, we provide clients differentiated investment ideas as well as deep-dive regulatory due diligence.
We Predict Policy,
Quantify Impact, and Recommend Strategy.
Corporations and investors lean on Capstone’s expertise in healthcare policy to gain valuable insights on regulatory risks and global opportunities. Our process is designed to uncover innovative policy-driven ideas, advising private equity firms, corporations, and investors on the impact of regulation on potential and existing investments.
We leverage our ability to wade through public records of existing and proposed regulation, legislation, and other policy efforts. We combine that with our relationships with major industry associations, as well as senior policymakers and influential experts, to add value and identify opportunities for investment growth.
Selected Issues
- Managed care
- Providers
- Medicaid
- Employee Retirement Income Security Act (ERISA)
- Affordable Care Act
- Pharmaceutical supply chain
- Health IT
- Long-term care
- Healthcare financial services
- Behavioral health
Case Studies
Capstone has a proven track record of providing in-depth analysis across a wide range of policy and regulatory issues. Our case studies demonstrate our healthcare team’s ability to help clients navigate complex policy challenges and develop targeted revenue-driving strategies.
Contact Us
Our Latest Healthcare Insights
How State Scrutiny Is Impacting Healthcare Private Equity Ownership
Created by Grace Totman, Co-Head of Capstone's Healthcare Practice Regulatory scrutiny around healthcare consolidation – specifically private equity investments – has increased over the past couple of years. Although federal investigations often receive the most...
The 340B Dilemma: The Power of Vague Law
July 21, 2025 By Angela Lamari, Capstone Healthcare analyst At only eight and a half pages of statute, the federal 340B drug pricing program is a clear example of how industry speaks when the law is silent. The program itself is fairly simple—in 1992, the government...
Policymaker Interest in Healthcare AI Heats Up
April 30, 2025 By Grace Totman, Co-Head of Capstone's Healthcare Practice Capstone believes that scrutiny of artificial intelligence (AI) in healthcare will increase state-level efforts to restrict its use, notably in utilization management (UM). This will create...
